Spots Global Cancer Trial Database for Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
Official Title: Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach
Study ID: NCT01956149
Conditions
Interventions
Study Description
Brief Summary: Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.
Detailed Description: 65 patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach will be treated with 20mg/m2 Cabazitaxel for a maximum of 6 cycles. Main objective of the study is the Disease Control Rate (DCR) with Cabazitaxel.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Krankenhaus Dresden Friedrichstadt, Dresden, , Germany
Krankenhaus Nordwest, Frankfurt am Main, , Germany
Universitätsklinikum Jena, Jena, , Germany
Contact Details
Name: Harald Schmalenberg, MD
Affiliation: Krankenhaus Dresden Friedrichstadt
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
